此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

接受高风险择期重大癌症手术 (PRS II) 的患者出院后基于风险的管理

2026年9月16日 更新者:Fox Chase Cancer Center

对接受高风险择期重大癌症手术 (PRS II) 的患者进行基于风险的出院后管理的随机对照试验

This is a randomized trial of intensified post-discharge surveillance (Intervention Arm) versus standard post-discharge surveillance (Control Arm).

研究概览

详细说明

Eligible adult patients with probable or histologically/cytologically confirmed, primary or recurrent, malignant neoplasms (any stage) scheduled to undergo elective major cancer surgery at FCCC who meet eligibility criteria will be stratified by procedure type and randomized to the Intervention Arm or Control Arm.

• Prior to discharge, patients who meet eligibility criteria at Second Registration will be confirmed for study eligibility and randomized. Patients in the Control Arm will receive standard post-discharge surveillance, as deemed appropriate/necessary by the surgeons caring for them at the time of hospital discharge.

Patients in the Intervention and Control Arms will be monitored

  • Through PDD 30 for postoperative deaths and complications (as defined by ACS NSQIP) and/or adverse events (as defined by CTCAE)
  • Through the end of the index hospitalization for ICU admission, postoperative LOS, return to operating room, and discharge to home.
  • Through PDD 90 for hospital readmission, QOL, and receipt of anti-neoplastic therapy

研究类型

介入性

注册 (实际的)

526

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19111-2497
        • Fox Chase Cancer Center - Philadelphia

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

First Registration Inclusion Criteria:

  • Age > 18 years at diagnosis
  • ECOG performance status 0, 1, or 2, defined as

Grade ECOG 0 Fully active, able to carry on all pre-disease performance without restriction

  1. Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work

  2. Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours

    • Patients must have probable (i.e., clinically suspicious) or histologically/cytologically confirmed, primary or recurrent, malignant neoplasm, malignant neuroendocrine tumor, or carcinoma in situ (any stage).

Patients undergoing major operations to resect or treat known or suspected malignancies of the head and neck, chest, abdomen, genitourinary tract, or extremities are eligible. Patients undergoing biopsies, outpatient procedures, superficial resections of cutaneous malignancies, or purely palliative operations are not eligible.

These procedures are commonly performed in patients with malignant neoplasms, malignant neuroendocrine tumors, or carcinomas in situ, and are commonly "tracked" by hospitals and cancer centers participating in the ACS NSQIP Procedure Targeted option because they are often associated with higher rates of postoperative morbidity and mortality (compared to other, less complex cancer procedures).

  • Patient must be scheduled for elective major cancer surgery (as listed in 4.1.4) at FCCC < 30 days after First Registration.

Elective surgery is defined as:

  • Patient is scheduled to be brought from their home (or normal living environment) to FCCC on the day of the index surgery (or day prior as scheduled admission) AND

  • Surgery is not scheduled as urgent or emergent

    • Ability to understand and willingness to sign a written informed consent and HIPAA consent document
    • Geographical accessibility and willingness to return to FCCC for all preoperative and postoperative study assessments.

First Registration Exclusion Criteria:

  • Any condition that might interfere with the subject's participation in the study, compliance with study requirements, or in the evaluation of the study results.

Second Registration Inclusion Criteria:

A patient will be eligible for continued inclusion in this study only if ALL of the following criteria apply at the time of Second Registration (one to two days prior to anticipated discharge). No exceptions or waivers will be granted for patients who do not meet the eligibility criteria.

  • Post

    • Elective (curative or palliative) major cancer surgery (as listed in 4.1.4 above) at the time of the index surgery (patient may have undergone more than one of these procedures) OR
    • Elective surgical procedure(s) listed as an option (i.e., CPT code) in the Surgical Risk Calculator webpage (patient may have undergone more than one of these procedures)

For the purposes of this study, the procedure that was performed with the highest estimated risk of DSC (as predicted by the Surgical Risk Calculator) will be denoted at the time of Second Registration as the "index procedure" performed during the "index surgery".

  • Elective surgery < 30 days after First Registration.

Second Registration Exclusion Criteria:

  • Status post elective surgical procedure(s) not listed as options in the Surgical Risk Calculator webpage. This includes patients whose scheduled procedure was suspended due to unexpected findings, such as carcinomatosis.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
有源比较器:Control Arm: Standard Perioperative Management

Patients in the Control Arm will receive standard post-discharge surveillance (i.e., usual care).

Patients in the Control Arm will receive standard post-discharge surveillance, as deemed appropriate/necessary by the surgeons caring for them at the time of hospital discharge.

实验性的:Intervention Arm: Intensified Post-Discharge Surveillance

Patients in the Intervention and Control Arms will be monitored

  • Through PDD 30 for postoperative deaths and complications (as defined by ACS NSQIP) and/or adverse events (as defined by CTCAE)
  • Through the end of the index hospitalization for ICU admission, postoperative LOS, return to operating room, and discharge to home.
  • Through PDD 90 for hospital readmission, QOL, and receipt of anti-neoplastic therapy
  • TCC Nurse Televisit at post-discharge day 1 and 7
  • Televisit with APP/Resident/Fellow between post-discharge day 3-5
  • Referral for home health nursing evaluation upon discharge

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
30-day rate of readmission/visit to emergency department/death
大体时间:30 days

The primary objective of this trial is to determine if intensified post-discharge surveillance leads to a 7% absolute risk reduction/35% relative risk reduction in the composite endpoint of 30-day rate of readmission/visit to emergency department/death compared to standard post discharge management in patients undergoing elective, high risk cancer operations.

30 days

次要结果测量

结果测量
措施说明
大体时间
30-day rate of death
大体时间:30 days

Secondary objectives of the study are to determine whether intensified post-discharge surveillance leads to a reduction in 30-day rate of death

30 days
30-day rate of hospital readmission after index surgery
大体时间:30 days

Secondary objectives of the study are to determine whether intensified post-discharge surveillance leads to a reduction in 30-day rate of hospital readmission after index surgery

30 days
60-day rate of hospital readmission after index surgery
大体时间:60 days

Secondary objectives of the study are to determine whether intensified post-discharge surveillance leads to a reduction in 60-day rate of hospital readmission after index surgery

60 days
90-day rate of hospital readmission after index surgery
大体时间:90 days

Secondary objectives of the study are to determine whether intensified post-discharge surveillance leads to a reduction in 90-day rate of hospital readmission after index surgery

90 days
30-day rate of unplanned Emergency Department visits
大体时间:30 days

Secondary objectives of the study are to determine whether intensified post-discharge surveillance leads to a reduction in 30-day rate of unplanned Emergency Department visits

30 days

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Jason Castellanos, MD、Fox Chase Cancer Center

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2022年10月14日

初级完成 (估计的)

2028年11月1日

研究完成 (估计的)

2028年11月1日

研究注册日期

首次提交

2022年7月7日

首先提交符合 QC 标准的

2022年7月7日

首次发布 (实际的)

2022年7月12日

研究记录更新

最后更新发布 (实际的)

2026年9月21日

上次提交的符合 QC 标准的更新

2026年9月16日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • 22-1013
  • SURG-210 (其他标识符:Fox Chase Cancer Center)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅